Tools / Drug approvals and letters / Drugs Tizanidine Hydrochloride Manages spasticity. Sold as Zanaflex, Ontralfy. Every FDA application for this active ingredient: 3 branded and 29 generic.
As of Nov 16, 2026, FDA lists 32 applications for Tizanidine Hydrochloride (sold as Zanaflex, Ontralfy), first approved Nov 27, 1996, with 0 new uses approved and 1 published complete response letter.
First approved : Nov 27, 1996 Applications : 32 New uses approved : 0 Complete response letters : 1 Medicare spending, 2025 : $81.3M
Medicare Spending CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name Product Part Spending, 2025 Change Beneficiaries Tizanidine HCl Part D $80.7M +5% 2,199,906 Zanaflex Part D $525K +15% 231
What Pharmacies Pay Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change TIZANIDINE HCL 2 MG CAPSULE: $0.090 per unit Generic · +5% in a year TIZANIDINE HCL 2 MG TABLET: $0.032 per unit Generic · -10% in a year TIZANIDINE HCL 4 MG CAPSULE: $0.101 per unit Generic · -13% in a year TIZANIDINE HCL 4 MG TABLET: $0.034 per unit Generic · -3% in a year TIZANIDINE HCL 6 MG CAPSULE: $0.144 per unit Generic · -4% in a year Clinical Trials 15 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted Effect of Metaxalone 640 mg (M640) on Driving, Cognition, and EEG Dynamics Compared to Tizanidine 8 mg in Adults Healthy Participant · Primus Pharmaceuticals Phase 4 Not yet recruiting Nov 12, 2026 Tizanidine Premedication Versus Placebo for Laryngeal Mask Airway Insertion and Recovery in Adults Undergoing Ambulatory Surgery Airway Management · Beni-Suef University Not applicable Not yet recruiting Nov 6, 2026 Phenotype-based Model for Managing Chronic Post-treatment Pain Among Head and Neck Cancer Survivors: a Pilot Study Chronic Postsurgical Pain, Chronic Post Cancer Surgery Pain · Shaukat Khanum Memorial Cancer Hospital & Research Centre Phase 2 Recruiting Nov 5, 2026 Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot Study Cancer Pain, Orofacial Pain · Shaukat Khanum Memorial Cancer Hospital & Research Centre Phase 2 Recruiting Nov 5, 2026 The Effect of Preoperative Administration of Oral Tizanidine on the Postoperative Pain and Sleep Quality The Effect of Preoperative Administration of Oral Tizanidine, Post Operative Pain · Tanta University Not applicable Recruiting Sep 2, 2026 Electrical Neuromodulation for Modifying Spinal Network Involved in Spasticity Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injury · University of Mississippi Medical Center Not applicable Active, not recruiting Aug 28, 2026 Postoperative Tizanidine Use in Pelvic Reconstructive Surgery: A Pilot Study Post Operative, Post Operative Analgesia · Hartford Hospital Phase 2 Recruiting Aug 17, 2026 Efficacy and Safety of Pregabalin/Tizanidine vs. Pregabalin in Patients With Fibromyalgia Fibromyalgia, Pregabalin · Beijing Tiantan Hospital Not applicable Not yet recruiting Feb 3, 2026
Applications NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing Nov 27, 1996 Zanaflex NDA 20397 · New molecular entity Legacy20 Marketed Jun 27, 2002 Tizanidine Hydrochloride ANDA 76280 Chartwell Rx5 Discontinued Jul 3, 2002 Tizanidine Hydrochloride ANDA 76284 Ani Pharms1 Discontinued Jul 3, 2002 Tizanidine Hydrochloride ANDA 76286 Dr Reddys Labs Inc7 Marketed Jul 12, 2002 Tizanidine Hydrochloride ANDA 76283 Ani Pharms0 Discontinued Aug 29, 2002 Zanaflex NDA 21447 · New dosage form Legacy6 Marketed Oct 11, 2002 Tizanidine Hydrochloride ANDA 76347 Epic Pharma LLC4 Marketed Mar 28, 2003 Tizanidine Hydrochloride ANDA 76354 Rising4 Marketed Apr 9, 2003 Tizanidine Hydrochloride ANDA 76371 Ani Pharms2 Discontinued Sep 29, 2003 Tizanidine Hydrochloride ANDA 76416 Sun Pharm Inds Inc3 Marketed Oct 20, 2003 Tizanidine Hydrochloride ANDA 76281 Tp Anda Holdings2 Marketed Dec 16, 2003 Tizanidine Hydrochloride ANDA 76282 Aurobindo Pharma USA2 Marketed Jan 16, 2004 Tizanidine Hydrochloride ANDA 76533 Apotex5 Marketed Sep 30, 2004 Tizanidine Hydrochloride ANDA 76321 Ani Pharms0 Discontinued Feb 3, 2012 Tizanidine Hydrochloride ANDA 78868 Apotex Inc3 Marketed Nov 9, 2012 Tizanidine Hydrochloride ANDA 91502 Pharmobedient2 Discontinued Nov 28, 2012 Tizanidine Hydrochloride ANDA 91283 Unichem Labs Ltd3 Marketed Jan 26, 2017 Tizanidine Hydrochloride ANDA 207170 Everest Lifesciences0 Discontinued Mar 3, 2017 Tizanidine Hydrochloride ANDA 208622 Zydus Pharms2 Marketed Mar 14, 2017 Tizanidine Hydrochloride ANDA 207199 Ph Health0 Discontinued Aug 4, 2017 Tizanidine Hydrochloride ANDA 209605 Jubilant Generics0 Marketed Mar 9, 2018 Tizanidine Hydrochloride ANDA 208187 Cadila2 Marketed Jan 25, 2019 Tizanidine Hydrochloride ANDA 211798 Alkem Labs Ltd1 Marketed Mar 12, 2019 Tizanidine Hydrochloride ANDA 210267 Ingenus Pharms LLC2 Marketed Mar 26, 2019 Tizanidine Hydrochloride ANDA 210021 Cadila Pharms Ltd1 Marketed Mar 27, 2019 Tizanidine Hydrochloride ANDA 212196 Alkem Labs Ltd2 Marketed Jan 13, 2020 Tizanidine Hydrochloride ANDA 213223 Alembic2 Marketed Mar 24, 2020 Tizanidine Hydrochloride ANDA 213544 Aurobindo Pharma Ltd1 Marketed May 27, 2020 Tizanidine Hydrochloride ANDA 213798 Rubicon Research0 Marketed May 13, 2024 Tizanidine Hydrochloride ANDA 213365 Pharmazone0 Marketed Aug 7, 2024 Tizanidine Hydrochloride ANDA 218920 Rising1 Marketed Dec 12, 2024 Ontralfy NDA 216190 · New dosage form Fidelity Biopharma0 Marketed
Complete Response Letters FDA's published letters for these applications Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA